Cargando…
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/ https://www.ncbi.nlm.nih.gov/pubmed/35448190 http://dx.doi.org/10.3390/curroncol29040216 |
_version_ | 1784691139699277824 |
---|---|
author | Yamai, Takuo Ikezawa, Kenji Kawamoto, Yasuharu Hirao, Takeru Higashi, Sena Daiku, Kazuma Maeda, Shingo Abe, Yutaro Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Ohkawa, Kazuyoshi |
author_facet | Yamai, Takuo Ikezawa, Kenji Kawamoto, Yasuharu Hirao, Takeru Higashi, Sena Daiku, Kazuma Maeda, Shingo Abe, Yutaro Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Ohkawa, Kazuyoshi |
author_sort | Yamai, Takuo |
collection | PubMed |
description | Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17 patients with UR-PC who initiated 5-FU/l-LV plus oxaliplatin (FOLFOX) as salvage chemotherapy at our hospital between June 2020 and August 2021, after treatment with GnP and 5-FU/LV plus nal-IRI. The primary endpoint was tumor response. The secondary endpoints were progression-free survival (PFS) and adverse events (AEs). The response and disease control rates were 5.9% (1/17) and 17.6% (3/17), respectively. The median PFS was 1.8 months (range: 0.4–5.2 months). Eight patients (47.1%) experienced grade 3 nonhematologic AEs, while none experienced grade 3 hematologic AEs. Two patients with controlled disease had homologous recombination deficiency (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations. |
format | Online Article Text |
id | pubmed-9026505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90265052022-04-23 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice Yamai, Takuo Ikezawa, Kenji Kawamoto, Yasuharu Hirao, Takeru Higashi, Sena Daiku, Kazuma Maeda, Shingo Abe, Yutaro Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Ohkawa, Kazuyoshi Curr Oncol Communication Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17 patients with UR-PC who initiated 5-FU/l-LV plus oxaliplatin (FOLFOX) as salvage chemotherapy at our hospital between June 2020 and August 2021, after treatment with GnP and 5-FU/LV plus nal-IRI. The primary endpoint was tumor response. The secondary endpoints were progression-free survival (PFS) and adverse events (AEs). The response and disease control rates were 5.9% (1/17) and 17.6% (3/17), respectively. The median PFS was 1.8 months (range: 0.4–5.2 months). Eight patients (47.1%) experienced grade 3 nonhematologic AEs, while none experienced grade 3 hematologic AEs. Two patients with controlled disease had homologous recombination deficiency (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations. MDPI 2022-04-11 /pmc/articles/PMC9026505/ /pubmed/35448190 http://dx.doi.org/10.3390/curroncol29040216 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Yamai, Takuo Ikezawa, Kenji Kawamoto, Yasuharu Hirao, Takeru Higashi, Sena Daiku, Kazuma Maeda, Shingo Abe, Yutaro Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Ohkawa, Kazuyoshi 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title | 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title_full | 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title_fullStr | 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title_full_unstemmed | 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title_short | 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice |
title_sort | 5-fluorouracil/l-leucovorin plus oxaliplatin (folfox) regimen as salvage chemotherapy for patients with unresectable pancreatic cancer receiving gemcitabine and nab-paclitaxel and 5-fluorouracil/l-leucovorin plus nanoliposomal irinotecan: preliminary results from clinical practice |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/ https://www.ncbi.nlm.nih.gov/pubmed/35448190 http://dx.doi.org/10.3390/curroncol29040216 |
work_keys_str_mv | AT yamaitakuo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT ikezawakenji 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT kawamotoyasuharu 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT hiraotakeru 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT higashisena 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT daikukazuma 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT maedashingo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT abeyutaro 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT urabemakiko 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT kaiyugo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT takadaryoji 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT nakaboritasuku 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT ueharahiroyuki 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice AT ohkawakazuyoshi 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice |